These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38052765)

  • 1. ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms.
    Arribas AJ; Napoli S; Cascione L; Barnabei L; Sartori G; Cannas E; Gaudio E; Tarantelli C; Mensah AA; Spriano F; Zucchetto A; Rossi FM; Rinaldi A; Castro de Moura M; Jovic S; Bordone Pittau R; Stathis A; Stussi G; Gattei V; Brown JR; Esteller M; Zucca E; Rossi D; Bertoni F
    Mol Cancer Ther; 2024 Mar; 23(3):368-380. PubMed ID: 38052765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms.
    Arribas AJ; Napoli S; Cascione L; Barnabei L; Sartori G; Cannas E; Gaudio E; Tarantelli C; Mensah AA; Spriano F; Zucchetto A; Rossi FM; Rinaldi A; de Moura MC; Jovic S; Pittau RB; Stathis A; Stussi G; Gattei V; Brown JR; Esteller M; Zucca E; Rossi D; Bertoni F
    bioRxiv; 2023 Jan; ():. PubMed ID: 36711490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
    Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
    PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
    Chiron D; Di Liberto M; Martin P; Huang X; Sharman J; Blecua P; Mathew S; Vijay P; Eng K; Ali S; Johnson A; Chang B; Ely S; Elemento O; Mason CE; Leonard JP; Chen-Kiang S
    Cancer Discov; 2014 Sep; 4(9):1022-35. PubMed ID: 25082755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
    Rexer BN; Chanthaphaychith S; Dahlman K; Arteaga CL
    Breast Cancer Res; 2014 Jan; 16(1):R9. PubMed ID: 24451154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma.
    Kim JH; Kim WS; Park C
    BMC Cancer; 2019 Oct; 19(1):936. PubMed ID: 31601188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A highly selective PI3Kδ inhibitor BGB-10188 shows superior preclinical anti-tumor activities and decreased on-target side effects on colon.
    Yang X; Bai H; Yuan X; Yang X; Liu Y; Guo M; Hu N; Jiang B; Lian Z; Ma Z; Wang J; Sun X; Zhang T; Su D; Wu Y; Li J; Wang F; Wang Z; Wang L; Liu X; Song X
    Neoplasia; 2024 Nov; 57():101053. PubMed ID: 39260132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TYM-3-98, a novel selective inhibitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B-cell lymphomas.
    Lou SY; Zheng FL; Tang YM; Zheng YN; Lu J; An H; Zhang EJ; Cui SL; Zhao HJ
    Life Sci; 2024 Jun; 347():122662. PubMed ID: 38670450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia.
    Scheffold A; Jebaraj BMC; Tausch E; Bloehdorn J; Ghia P; Yahiaoui A; Dolnik A; Blätte TJ; Bullinger L; Dheenadayalan RP; Li L; Schneider C; Chen SS; Chiorazzi N; Dietrich S; Seiffert M; Tannheimer S; Döhner H; Mertens D; Stilgenbauer S
    Blood; 2019 Aug; 134(6):534-547. PubMed ID: 31010847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis.
    Arribas AJ; Napoli S; Cascione L; Sartori G; Barnabei L; Gaudio E; Tarantelli C; Mensah AA; Spriano F; Zucchetto A; Rossi FM; Rinaldi A; Castro de Moura M; Jovic S; Bordone-Pittau R; Di Veroli A; Stathis A; Cruciani G; Stussi G; Gattei V; Brown JR; Esteller M; Zucca E; Rossi D; Bertoni F
    Haematologica; 2022 Nov; 107(11):2685-2697. PubMed ID: 35484662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma.
    Jiang VC; Liu Y; Lian J; Huang S; Jordan A; Cai Q; Lin R; Yan F; McIntosh J; Li Y; Che Y; Chen Z; Vargas J; Badillo M; Bigcal JN; Lee HH; Wang W; Yao Y; Nie L; Flowers CR; Wang M
    J Clin Invest; 2023 Feb; 133(3):. PubMed ID: 36719376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SAF-248, a novel PI3Kδ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma.
    Zhang X; Duan YT; Wang Y; Zhao XD; Sun YM; Lin DZ; Chen Y; Wang YX; Zhou ZW; Liu YX; Jiang LH; Geng MY; Ding J; Meng LH
    Acta Pharmacol Sin; 2022 Jan; 43(1):209-219. PubMed ID: 33782541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase
    Shin N; Stubbs M; Koblish H; Yue EW; Soloviev M; Douty B; Wang KH; Wang Q; Gao M; Feldman P; Yang G; Hall L; Hansbury M; O'Connor S; Leffet L; Collins R; Katiyar K; He X; Waeltz P; Collier P; Lu J; Li YL; Li Y; Liu PCC; Burn T; Covington M; Diamond S; Shuey D; Roberts A; Yeleswaram S; Hollis G; Metcalf B; Yao W; Huber R; Combs A; Newton R; Scherle P
    J Pharmacol Exp Ther; 2020 Jul; 374(1):211-222. PubMed ID: 32345620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
    Canfield K; Li J; Wilkins OM; Morrison MM; Ung M; Wells W; Williams CR; Liby KT; Vullhorst D; Buonanno A; Hu H; Schiff R; Cook RS; Kurokawa M
    Cell Cycle; 2015; 14(4):648-55. PubMed ID: 25590338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
    Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
    Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.
    Yang G; Wang J; Tan L; Munshi M; Liu X; Kofides A; Chen JG; Tsakmaklis N; Demos MG; Guerrera ML; Xu L; Hunter ZR; Che J; Patterson CJ; Meid K; Castillo JJ; Munshi NC; Anderson KC; Cameron M; Buhrlage SJ; Gray NS; Treon SP
    Blood; 2021 Nov; 138(20):1966-1979. PubMed ID: 34132782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance.
    Gayle SS; Arnold SL; O'Regan RM; Nahta R
    Anticancer Agents Med Chem; 2012 Feb; 12(2):151-62. PubMed ID: 22043997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.
    Kapoor I; Li Y; Sharma A; Zhu H; Bodo J; Xu W; Hsi ED; Hill BT; Almasan A
    Cell Death Dis; 2019 Dec; 10(12):924. PubMed ID: 31801949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
    Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
    Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
    [No Abstract]   [Full Text] [Related]  

  • 20. Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas.
    Spriano F; Tarantelli C; Gaudio E; Gerlach MM; Priebe V; Cascione L; Bernasconi E; Targa A; Mascia M; Dirnhofer S; Stathis A; Zucca E; Bertoni F
    Br J Haematol; 2019 Dec; 187(5):595-601. PubMed ID: 31355927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.